Alexandra Mazharian

This study uses CRISPR/Cas9 to delete Shp1 and Shp2 in human CD34+ cells, showing Shp2 is critical for megakaryopoiesis and thrombopoiesis while Shp1 is not.

This study shows that deleting Shp1 and Shp2 in mice impairs megakaryopoiesis and thrombopoiesis, leading to macrothrombocytopenia and reduced platelet function.

This study introduces CAPRIs, bispecific antibodies that inhibit platelet activation by clustering G6B with ITAM receptors, showing effectiveness in preventing thrombus formation without causing bleeding.